136 related articles for article (PubMed ID: 26767086)
1. Rapid Extensive Recurrence of Triple Negative Breast Cancer: Are Both Therapy and Cancer Biology the Culprit?
Vyas D; Deshpande K; Chaturvedi L; Gieric L; Ching K
J Clin Med Res; 2016 Feb; 8(2):162-7. PubMed ID: 26767086
[TBL] [Abstract][Full Text] [Related]
2. A Second-Generation Proteasome Inhibitor and Doxorubicin Modulates IL-6, pSTAT-3 and NF-kB Activity in MDA-MB-231 Breast Cancer Cells.
Vyas D; Lopez-Hisijos N; Shah P; Deshpande KS; Basson MD; Vyas A; Chaturvedi LS
J Nanosci Nanotechnol; 2017 Jan; 17(1):175-85. PubMed ID: 29617099
[TBL] [Abstract][Full Text] [Related]
3. Elevated estrogen receptor β expression in triple negative breast cancer cells is associated with sensitivity to doxorubicin by inhibiting the PI3K/AKT/mTOR signaling pathway.
Lei S; Fan P; Wang M; Zhang C; Jiang Y; Huang S; Fang M; He Z; Wu A
Exp Ther Med; 2020 Aug; 20(2):1630-1636. PubMed ID: 32742395
[TBL] [Abstract][Full Text] [Related]
4. KIFC1: A Reliable Prognostic Biomarker in Rb-positive Triple-negative Breast Cancer Patients Treated With Doxorubicin in Combination With Abemaciclib.
Fleisher B; Werkman C; Jacobs B; Varkey J; Taha K; Ait-Oudhia S
Cancer Diagn Progn; 2022; 2(5):525-532. PubMed ID: 36060015
[TBL] [Abstract][Full Text] [Related]
5. Doxorubicin-polyglycerol-nanodiamond conjugate is a cytostatic agent that evades chemoresistance and reverses cancer-induced immunosuppression in triple-negative breast cancer.
Yuan SJ; Xu YH; Wang C; An HC; Xu HZ; Li K; Komatsu N; Zhao L; Chen X
J Nanobiotechnology; 2019 Oct; 17(1):110. PubMed ID: 31623629
[TBL] [Abstract][Full Text] [Related]
6. Next-generation proteasome inhibitor oprozomib enhances sensitivity to doxorubicin in triple-negative breast cancer cells.
Shi Y; Bieerkehazhi S; Ma H
Int J Clin Exp Pathol; 2018; 11(5):2347-2355. PubMed ID: 31938346
[TBL] [Abstract][Full Text] [Related]
7. Substance P Receptor Signaling Mediates Doxorubicin-Induced Cardiomyocyte Apoptosis and Triple-Negative Breast Cancer Chemoresistance.
Robinson P; Kasembeli M; Bharadwaj U; Engineer N; Eckols KT; Tweardy DJ
Biomed Res Int; 2016; 2016():1959270. PubMed ID: 26981525
[TBL] [Abstract][Full Text] [Related]
8. Glutamine-β-cyclodextrin for targeted doxorubicin delivery to triple-negative breast cancer tumors via the transporter ASCT2.
Zhou P; Liang X; Zhou C; Qin J; Hou C; Zhu Z; Zhang W; Wang S; Zhong D
J Mater Chem B; 2019 Sep; 7(35):5363-5375. PubMed ID: 31403158
[TBL] [Abstract][Full Text] [Related]
9. Metabolomics Analysis Reveals Altered Metabolic Pathways and Response to Doxorubicin in Drug-Resistant Triple-Negative Breast Cancer Cells.
Rushing BR; Molina S; Sumner S
Metabolites; 2023 Jul; 13(7):. PubMed ID: 37512572
[TBL] [Abstract][Full Text] [Related]
10. TRPV2 is a novel biomarker and therapeutic target in triple negative breast cancer.
Elbaz M; Ahirwar D; Xiaoli Z; Zhou X; Lustberg M; Nasser MW; Shilo K; Ganju RK
Oncotarget; 2018 Sep; 9(71):33459-33470. PubMed ID: 30323891
[TBL] [Abstract][Full Text] [Related]
11. Stat3/Oct-4/c-Myc signal circuit for regulating stemness-mediated doxorubicin resistance of triple-negative breast cancer cells and inhibitory effects of WP1066.
Cheng CC; Shi LH; Wang XJ; Wang SX; Wan XQ; Liu SR; Wang YF; Lu Z; Wang LH; Ding Y
Int J Oncol; 2018 Jul; 53(1):339-348. PubMed ID: 29750424
[TBL] [Abstract][Full Text] [Related]
12. Chemoresistance in the Human Triple-Negative Breast Cancer Cell Line MDA-MB-231 Induced by Doxorubicin Gradient Is Associated with Epigenetic Alterations in Histone Deacetylase.
Han J; Lim W; You D; Jeong Y; Kim S; Lee JE; Shin TH; Lee G; Park S
J Oncol; 2019; 2019():1345026. PubMed ID: 31275376
[TBL] [Abstract][Full Text] [Related]
13. Combined mTOR inhibitor rapamycin and doxorubicin-loaded cyclic octapeptide modified liposomes for targeting integrin α3 in triple-negative breast cancer.
Dai W; Yang F; Ma L; Fan Y; He B; He Q; Wang X; Zhang H; Zhang Q
Biomaterials; 2014 Jul; 35(20):5347-5358. PubMed ID: 24726747
[TBL] [Abstract][Full Text] [Related]
14. Anti-Trop2 antibody-conjugated bioreducible nanoparticles for targeted triple negative breast cancer therapy.
Son S; Shin S; Rao NV; Um W; Jeon J; Ko H; Deepagan VG; Kwon S; Lee JY; Park JH
Int J Biol Macromol; 2018 Apr; 110():406-415. PubMed ID: 29055700
[TBL] [Abstract][Full Text] [Related]
15. Enhancing accrual to chemotherapy trials for patients with early stage triple-negative breast cancer: a survey of physicians and patients.
Jacobs C; Clemons M; Mazzarello S; Hutton B; Joy AA; Brackstone M; Freedman O; Vandermeer L; Ibrahim M; Fergusson D; Hilton J
Support Care Cancer; 2017 Jun; 25(6):1881-1886. PubMed ID: 28127659
[TBL] [Abstract][Full Text] [Related]
16. Current strategy for triple-negative breast cancer: appropriate combination of surgery, radiation, and chemotherapy.
Yagata H; Kajiura Y; Yamauchi H
Breast Cancer; 2011 Jul; 18(3):165-73. PubMed ID: 21290263
[TBL] [Abstract][Full Text] [Related]
17. Doxorubicin-Loaded Micelle Targeting MUC1: A Potential Therapeutic for MUC1 Triple Negative Breast Cancer Treatment.
Khondee S; Chittasupho C; Tima S; Anuchapreeda S
Curr Drug Deliv; 2018; 15(3):406-416. PubMed ID: 28707580
[TBL] [Abstract][Full Text] [Related]
18. Cancer-associated fibroblasts induce high mobility group box 1 and contribute to resistance to doxorubicin in breast cancer cells.
Amornsupak K; Insawang T; Thuwajit P; O-Charoenrat P; Eccles SA; Thuwajit C
BMC Cancer; 2014 Dec; 14():955. PubMed ID: 25512109
[TBL] [Abstract][Full Text] [Related]
19. Apatinib-induced NF-κB inactivation sensitizes triple-negative breast cancer cells to doxorubicin.
Tang D; Ma J; Chu Z; Wang X; Zhao W; Zhang Q
Am J Transl Res; 2020; 12(7):3741-3753. PubMed ID: 32774731
[TBL] [Abstract][Full Text] [Related]
20. Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer.
Basho RK; Yam C; Gilcrease M; Murthy RK; Helgason T; Karp DD; Meric-Bernstam F; Hess KR; Valero V; Albarracin C; Litton JK; Chavez-MacGregor M; Hong D; Kurzrock R; Hortobagyi GN; Janku F; Moulder SL
Oncologist; 2018 Nov; 23(11):1300-1309. PubMed ID: 30139837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
